Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on August 17, 2023. The filing primarily addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors and the Audit Committee.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses on personnel appointments rather than financial performance data.
Material Changes
The material change reported is the appointment of Bethany L. Sensenig as a member of the Board of Directors and the Audit Committee, effective August 17, 2023.
Compensatory Arrangements and Governance
- Cash Compensation: Ms. Sensenig will receive $62,500 in 2023, prorated for her actual time of service.
- Equity Grant: The Board granted options to purchase 24,153 shares of common stock under the 2021 Equity Incentive Plan.
- Exercise Price: The per-share exercise price is set at $30.22.
- Vesting: The options are subject to a four-year vesting period.
- Related Party Transactions: The filing states there were no undisclosed arrangements or transactions requiring reporting under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the exact vesting schedule and performance conditions (if any) for the 24,153 stock options granted to Ms. Sensenig.
- Confirm the total number of outstanding shares and the impact of this grant on potential dilution.
- Review the full text of the press release (Exhibit 99.1) for additional biographical details on Ms. Sensenig's qualifications.
- Check subsequent filings for the final prorated cash compensation amount paid for the remainder of 2023.